Maze Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Maze Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MAZE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001842295
Board of directors
-
Alan Colowick · DirectorSince 2025
-
Catherine A. Sohn · DirectorSince 2025
-
Charles J. Homcy · DirectorSince 2025
- Since 2025
-
Herve Hoppenot · DirectorSince 2025
-
James Brush · DirectorSince 2025
-
Jason Coloma V · Director · Chief Executive OfficerSince 2025
-
Jeffrey K. Tong · DirectorSince 2025
-
Jonathan E. Lim · DirectorSince 2025
-
Nancy C. Andrews · DirectorSince 2025
-
Neil Exter · DirectorSince 2025
-
Neil Kumar · DirectorSince 2026
-
Paula A. Johnson · DirectorSince 2026
-
Richard H. Scheller · DirectorSince 2025
-
Sekar Kathiresan · DirectorSince 2025
-
Sophie Kornowski · DirectorSince 2026
Chief executives
Jason Coloma V
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 8, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
81.6%
-
85.8%
Board connections
13 of this board's directors also sit on 21 other boards.
- via Charles J. Homcy, Neil Kumar and Richard H. Scheller
- via Richard H. Scheller
- via Catherine A. Sohn
- via Alan Colowick
- via Herve Hoppenot
- via Jonathan E. Lim
- via Jason Coloma V
- via Neil Kumar
- via Nancy C. Andrews
- via Jonathan E. Lim
- via Herve Hoppenot
- via Catherine A. Sohn
- via Paula A. Johnson
- via Daniel K. Spiegelman
- via Daniel K. Spiegelman
- via Alan Colowick
- via Jeffrey K. Tong
- via Sekar Kathiresan
- via Jeffrey K. Tong
- via Daniel K. Spiegelman
- via Daniel K. Spiegelman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $22,101,674
- 91 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 4, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Open-market sale | −9,705 | $26.22 | $254,502 |
| Sep 3, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Open-market sale | −5,130 | $26.01 | $133,448 |
| Sep 3, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −11,282 | $26.01 | $293,482 |
| Sep 3, 2026 | Courtney Phillips Officer (GC and Corp. Secretary) | Open-market sale | −1,990 | $26.01 | $51,766 |
| Sep 3, 2026 | Dandekar Atul Officer (CSBO) | Open-market sale | −3,207 | $26.01 | $83,425 |
| Sep 3, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Open-market sale | −59 | $25.78 | $1,521 |
| Sep 3, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −129 | $25.77 | $3,325 |
| Sep 3, 2026 | Courtney Phillips Officer (GC and Corp. Secretary) | Open-market sale | −22 | $25.78 | $567 |
| Sep 3, 2026 | Dandekar Atul Officer (CSBO) | Open-market sale | −36 | $25.81 | $929 |
| Sep 2, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Open-market sale | −4,481 | $26.38 | $118,191 |
| Sep 2, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −9,852 | $26.38 | $259,856 |
| Sep 2, 2026 | Courtney Phillips Officer (GC and Corp. Secretary) | Open-market sale | −1,738 | $26.38 | $45,841 |
| Sep 2, 2026 | Dandekar Atul Officer (CSBO) | Open-market sale | −2,800 | $26.38 | $73,853 |
| Sep 2, 2026 | Bernstein Harold Officer (President, R&D & CMO) | Open-market sale | −625 | $27.12 | $16,951 |
| Sep 2, 2026 | Jason Coloma V Director, Officer (Chief Executive Officer) | Open-market sale | −1,375 | $27.12 | $37,292 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.